Sponsors Show Major Improvement in Investigative Site Relationships
In a recent CenterWatch survey, investigative sites rated sponsor companies on more than 36 individual relationship attributes.
In a recent CenterWatch survey, investigative sites rated sponsor companies on more than 36 individual relationship attributes. The top five highest-rated large sponsors-those with 2013 total revenue from drug sales greater than $11 billion-were Novo Nordisk, Takeda, GlaxoSmithKline, AstraZeneca and Janssen. The top five mid-sized and small sponsors-with 2013 total revenue from drug sales less than $11 billion-were Servier, Celgene, Biogen Idec, Otsuka and Forest Laboratories (acquired by Actavis last year). This survey also marks one of the few times in almost 20 years that strong improvement was observed in sponsors narrowing their performance gaps across attributes that sites rate as most important in defining relationship effectiveness.
Relationship attributes that sites rate as most important in defining relationship effectiveness include quality of monitors, study support and easily accessible staff to resolve problems.With the current industry-wide focus on patient centric clinical trials, sponsors have invested more time and resources in their investigative site relationships with the ultimate goal to better engage and enhance study volunteer participation experiences. To achieve this goal, sponsors have implemented a number of initiatives to reduce protocol complexity and improve study feasibility, efficiency and convenience.
Read the full release here.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
